Related Experiment Video

Updated: Sep 26, 2026

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin

Mark D Savellano1, Tayyaba Hasan

  • 1Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

Photochemistry and Photobiology
|May 8, 2003
PubMed

Insights

Researchers developed a new method to create stable, water-soluble photosensitizer immunoconjugates (PICs) for photoimmunotherapy. This innovation improves PICs for potential cancer treatment, showing significant cell killing in preclinical models.

Area of Science:

  • Bioconjugation Chemistry
  • Photodynamic Therapy
  • Cancer Therapeutics

Background:

  • Photoimmunotherapy (PIT) has shown promise but is limited by challenges in creating high-quality photosensitizer immunoconjugates (PICs).
  • Existing methods struggle with PIC solubility, aggregation, and purity, hindering clinical translation.

Purpose of the Study:

  • To develop an innovative conjugation method for producing stable, water-soluble PICs suitable for photoimmunotherapy.
  • To characterize the resulting PICs and evaluate their efficacy in vitro.

Main Methods:

  • Utilized polyethylene glycol (PEG)ylation of antibody lysines to enhance solubility and reduce aggregation.
  • Employed a dual-solvent system (DMSO/water) to prevent photosensitizer aggregation and non-covalent interactions.
  • Conjugated BPD Verteporfin (BPD) to C225 anti-EGFR antibody, followed by purification and characterization.

Main Results:

  • Successfully produced water-soluble, aggregate-free PICs with controlled BPD loading (< or = 11 BPD/antibody).
  • PEGylated PICs maintained antigen-binding activity and reduced non-specific cellular uptake.
  • C225 PICs demonstrated potent photodynamic killing of EGFR-overexpressing A-431 cells (90% viability reduction) with minimal effect on EGFR-negative cells.

Conclusions:

  • The novel PEGylation and dual-solvent method enables the production of high-quality PICs for photoimmunotherapy.
  • PEGylated BPD-C225 PICs show significant potential for treating EGFR-overexpressing cancers.
  • Further investigation in animal models is warranted.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.